United Kingdom

Therapix Biosciences Ltd (TRPX.OQ)

TRPX.OQ on NASDAQ Stock Exchange Capital Market

15 Dec 2017
Change (% chg)

$-0.04 (-0.75%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Therapix Biosciences Q3 loss per share $0.30
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Therapix Biosciences Ltd : :Therapix Biosciences reports third quarter 2017 financial results and provides business update.Q3 loss per share $0.30.Therapix Biosciences Ltd - ‍cash totaled $10.7 Million as of September 30, 2017, compared to $11.8 million as of June 30, 2017​.  Full Article

Therapix Biosciences and Assuta Medical Center to initiate clinical trial in obstructive sleep apnea
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Therapix Biosciences Ltd :Therapix Biosciences and Assuta Medical Center to initiate clinical trial in obstructive sleep apnea.  Full Article

Therapix biosciences says CEO Dr. Haber resigned
Wednesday, 24 May 2017 

May 24 (Reuters) - Therapix Biosciences Ltd :Therapix biosciences announces ceo change.Says ceo dr haber resigned.Therapix biosciences ltd - board of directors is undertaking a search to identify a permanent, u.s. Based chief executive officer.  Full Article

Therapix Biosciences files application with FDA for an Orphan designation for Tourette's Syndrome drug
Wednesday, 15 Jun 2016 

: Therapix biosciences ltd says estimates that an initial clinical trial will begin in h2/2016 .Therapix biosciences filed an application with the fda to approve an "orphan" designation for the drug developed based on the entourage technology for treating tourette's syndrome.  Full Article

Therapix expects to have results of Tourette's drug trial by end of Q1

TEL AVIV, Dec 4 Israel's Therapix Biosciences said on Monday it expects by the end of March to have the results from its mid-stage trial of a cannabinoid-based drug for treating Tourette's syndrome which could be worth billions of dollars in revenues.